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ABBREVIATIONS  
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UK  United Kingdom  
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ABSTRACT 
Oral bisphosphonates are the most commonly used drugs to treat post-menopausal 
osteoporosis. Acute pseudogout is anecdotally reported to occur following bisphosphonate 
initiation but empirical data are lacking. We investigated whether treatment with oral 
bisphosphonates is a risk factor for incident acute pseudogout. 
 
A matched case-control study was undertaken using data from the UK-Clinical Practice 
Research Datalink (CPRD). Adults who consulted for incident acute pseudogout between 
1987 and 2012 were each matched for gender, age at pseudogout diagnosis, and general 
practice to up to four control subjects without pseudogout. The exposure of interest was a 
prescription for an oral bisphosphonate issued within the 60-day period prior to the date of 
incident acute pseudogout. Associations between incident acute pseudogout and prior 
bisphosphonate prescription were examined using conditional logistic regression, adjusting 
for hyperparathyroidism, osteoarthritis, rheumatoid arthritis, haemochromatosis, 
hypophosphatasia, and prescriptions for diuretics and oral corticosteroids. 
 
2011 acute pseudogout cases were compared to 8013 matched controls without acute 
pseudogout (mean age (SD) 72 years (14); 52% male). 123 cases (6.1%) had received an oral 
bisphosphonate prescription in the 60-day exposure period compared with 305 controls 
(3.8%) (adjusted incidence rate ratio 1.33; 95% confidence interval 1.05 to 1.69). This 
association was stronger in females (adjusted incidence rate ratio 1.49; 95% confidence 
interval 1.15 to 1.94) and was non-significant in males (0.83; 0.48 to 1.44). 
 
Incident acute pseudogout was associated with prescription of an oral bisphosphonate in the 
preceding 60 days. Prescribers should be aware of acute pseudogout as a possible side-effect 
of bisphosphonate treatment. Further research is needed to explore the risks conferred by 
different bisphosphonates and the mechanism underlying this association.  
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INTRODUCTION 
Calcium pyrophosphate crystal deposition (CPPD) is a common idiopathic age-related 
phenomenon. Clinical presentations are varied and include asymptomatic radiographic 
chondrocalcinosis, chronic arthropathy, and, most dramatically, acute attacks of joint pain 
and swelling which most commonly affect the knee (acute pseudogout /acute calcium 
pyrophosphate (CPP) crystal arthritis).
1
 The prevalence of radiographic chondrocalcinosis in 
adults aged over 40 years is 4.5%, and rises sharply with age, peaking at 18% in people aged 
over 80 years.
2
  Less commonly, CPPD can occur secondary to metabolic disorders, namely 
haemochromatosis, hyperparathyroidism, hypomagnesaemia and hypophosphatasia, or rarer 
familial aggregation.
3-7
 Diuretic use has been suggested to be a risk factor for radiographic 
chondrocalcinosis and acute pseudogout, and is thought to act via renal magnesium loss.
2,8
 
Several case reports describe the occurrence of acute pseudogout following initiation 
of treatment with oral and intravenous bisphosphonates,
9-14
 raising the possibility that 
bisphosphonate therapy is also a risk factor for CPPD.  Bisphosphonates are synthetic 
analogues of pyrophosphate and are potent inhibitors of bone resorption, achieved by the 
inhibition of osteoclasts.
15
 They are most commonly used as treatment for post-menopausal 
osteoporosis but other licensed indications include other forms of osteoporosis, Paget’s 
disease, hypercalcaemia and metastatic bone disease.
16,17
 Oral alendronic acid, the most 
commonly prescribed bisphosphonate, accounted for 7.4 million items dispensed in the 
community in England in 2014.
18
 The most commonly experienced adverse events are upper 
gastrointestinal symptoms although rarer side-effects include osteonecrosis of the jaw and 
atypical femoral fractures.
19,20
 Several plausible biological mechanisms exist via which 
bisphosphonates could predispose to formation and shedding of CPP crystals. 
Bisphosphonates can lower serum calcium levels acutely, a phenomenon described in three 
published case reports of bisphosphonate-induced acute pseudogout,
10,12,13
 which could 
theoretically precipitate the shedding of CPP crystals from articular cartilage into synovial 
fluid.
21
  Disodium etidronate inhibits renal phosphate excretion, raising serum phosphate 
levels and thereby predisposing to CPPD.
22
 Furthermore, bisphosphonates are pyrophosphate 
analogues and impair CPP crystal dissolution via an inhibitory effect on the pyrophosphatase 
activity of alkaline phosphatase.
23
 
Despite these potential mechanisms, there have been no empirical research studies to 
examine the occurrence of acute pseudogout as a complication of bisphosphonate treatment. 
The aim of this matched case-control study was to investigate whether treatment with oral 
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bisphosphonates is a risk factor for incident acute pseudogout in a primary care population, 
and to examine whether different oral bisphosphonates confer the same risk. 
 
METHODS 
CPRD 
The UK Clinical Practice Research Datalink (CPRD) is the largest database of electronic 
primary care health records in the world. It is a repository of clinical data from over 600 
general practices in the England and Wales, covering 5.5 million people, and includes records 
of consultations, prescriptions, referrals and investigations. To be included in CPRD, the 
quality of data provided by contributing practices must meet stringent criteria and be 
considered to be “up to standard” for research purposes.24 Previous studies of the 
epidemiology of inflammatory conditions including crystal arthropathies have been 
undertaken using data from CPRD
25-30 
and a high validity of diagnosis has been reported.
24,31
 
The study was approved by the CPRD Independent Scientific Advisory Committee (protocol 
13_103).  
 
Sample selection 
Cases 
The outcome of interest was incident acute pseudogout. Cases were selected as all adults 
aged 18 years and over with a first recorded Read-coded diagnosis of pseudogout between 
01/03/1987 and 31/12/2012. In those with multiple codes for pseudogout, only the first 
occurrence of the condition was included in analyses. Pseudogout was defined by the single 
Read code N02..14.
8
 
 
Controls 
Each case was individually matched to up to four individuals who did not have a diagnosis of 
pseudogout up to the ‘index date’ of their matched case (i.e. the date on which the case was 
diagnosed with pseudogout) using concurrent sampling. Matching was on the basis of general 
practice, gender and age (within 3 years) at the index date. Controls were also required to 
have consulted with the practice in the year that the matched case was diagnosed with 
pseudogout, thus ensuring that controls were active members of the practice and reducing the 
possibility of artificially inflating the consultation rates of cases by comparing them to ‘non-
consulters’. 
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In order to ensure high quality data in the exposure period, all cases and controls were 
required to have 6 months of up-to-standard data prior to the index date. 
 
Exposure 
The exposure of interest was a prescription for an oral bisphosphonate issued within the 60-
day period prior to the index date. Codes used to define oral bisphosphonates are available 
from the authors on request. Intravenous bisphosphonates were not considered as these are 
not prescribed in primary care in the UK
18
 and, as a result, are not routinely recorded in 
CPRD. 
 
Potential confounding variables 
Potential confounders of the association between oral bisphosphonates and pseudogout were 
considered to be a diagnosis of hyperparathyroidism, osteoarthritis (OA), rheumatoid arthritis 
(RA), haemochromatosis or hypophosphatasia, or a prescription for diuretics (loop or 
thiazide) or oral corticosteroids. Medical diagnoses were identified by Read code. Since these 
medical conditions are chronic in nature, entry of a Read code for these conditions recorded 
at any point prior to the index date was considered to indicate presence of the disease. 
Prescription records were searched for prescription of diuretics or oral corticosteroids in the 
60 days prior to the index date. Read codes and prescription codes used to identify medical 
diagnoses and medications are available from the authors on request. 
 
Power calculation 
An a priori feasibility count undertaken by the CPRD knowledge centre estimated that 2147 
eligible cases of pseudogout would be identified in the study period. Matching these cases to 
controls in a ratio of 1:4, and assuming a rate of exposure to bisphosphonates in the controls 
of 1.6%, along with a correlation of exposure between cases and controls of 0.2 and a 5% 
significance level, it was estimated that the study would have approximately 98% power to 
detect an odds ratio of 2.0. 
 
Statistical analysis 
Unadjusted conditional logistic regression was used to assess the association between oral 
bisphosphonate prescriptions and incident acute pseudogout status in all analyses. Analyses 
were first conducted for all oral bisphosphonates combined and then separately for individual 
oral bisphosphonate preparations (alendronic acid, disodium etidronate, ibandronic acid, 
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risedronate sodium, sodium clodronate, tiludronate disodium). Models were then adjusted for 
hyperparathyroidism, OA, RA, haemochromatosis, hypophosphatasia, and prescriptions in 
the 60 days prior to the index date of diuretics and oral corticosteroids. As control subjects 
were identified by risk set sampling, the odds ratios from all analyses can be interpreted, and 
so are presented, as incidence rate ratios (IRR) with 95% confidence intervals (95%CI).  
Three sensitivity analyses were performed. First, the primary analysis of the 
association between prescription of all oral bisphosphonates in the 60 days prior to the index 
date and incident acute pseudogout was repeated after excluding matched case and controls in 
whom the pseudogout case had received their first bisphosphonate prescription greater than 
60 days prior to the index date in order to investigate whether any association arises from 
cumulative or incident bisphosphonate exposure. Second, in order to address the possibility 
of misclassification bias (i.e. patients with gout being misclassified as having pseudogout), 
the primary analyses were repeated having excluded any individuals (cases or controls) who 
had a diagnosis of gout prior to the index date. Third, in order to investigate who may be 
susceptible to any increased risk of incident pseudogout following prescription of 
bisphosphonates, models were fitted with interaction terms separately for age and gender 
where any significant associations were found in the main analyses. The significance of 
interaction terms was assessed using likelihood ratio tests. 
All analyses were conducted in Stata MP2 14.1.
32
 
 
RESULTS 
During the study period, 2011 individuals with an incident diagnosis of pseudogout were 
identified and successfully matched for gender, age at pseudogout diagnosis, and general 
practice to 8013 control subjects without pseudogout (table 1). Mean age of pseudogout 
cases was 72.0 years (standard deviation 13.5) and 1051 (52.3%) were male. 
Hyperparathyroidism, OA, RA, prescription of oral corticosteroids, and gout were more 
prevalent in the pseudogout cases than control subjects (table 1). 
One-hundred and twenty-three pseudogout cases (6.1%) had received a prescription 
for an oral bisphosphonate in the 60-day period preceding the index date compared with 305 
(3.8%) controls (unadjusted IRR 1.69; 95%CI 1.35 to 2.12). After adjustment for 
hyperparathyroidism, OA, RA, and prescriptions for diuretics and oral corticosteroids, this 
association attenuated slightly (IRR 1.33; 95%CI 1.05 to 1.69). Owing to the very small 
numbers of patients identified with haemochromatosis and hypophosphatasia (table 1), these 
diagnoses were not included as covariates in the model. In undertaking the first sensitivity 
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analysis to investigate the effect of cumulative or incident bisphosphonate exposure, we 
found that all pseudogout cases initiated a bisphosphonate within the period 60 days prior to 
the index date, therefore replicating the main analysis. 
The most commonly used oral bisphosphonate was alendronic acid (table 2). Eighty-
four pseudogout cases (4.2%) received a prescription for alendronic acid in the 60-day period 
preceding the index date compared with 211 (2.6%) controls (adjusted IRR 1.36; 95%CI 1.03 
to 1.79). Positive associations between prescription during the 60 days prior to the index date 
and incident pseudogout were seen for disodium etidronate, risedronate sodium and sodium 
clodronate whereas a negative association was seen for ibandronic acid. These associations 
were not statistically significant although the numbers of prescriptions for these drugs were 
small. No participants were prescribed tiludronate disodium. 
After excluding participants with a diagnosis of gout prior to the index date, the 
significant associations with any oral bisphosphonate (adjusted IRR 1.43; 95%CI 1.11 to 
1.85) and alendronic acid (1.53; 1.15 to 2.06) in the 60 days prior to pseudogout were slightly 
stronger (table 3).  
The association between prescription of any oral bisphosphonate in the 60 days prior 
to index date was stronger in females (adjusted IRR 1.49; 95%CI 1.15 to 1.94) and was non-
significant in males (0.83; 0.48 to 1.44) (p-value for interaction; unadjusted 0.121; adjusted 
0.048) and diminished with age, although there was no significant association in any age-
group (p-value for interaction; unadjusted 0.610, adjusted 0.781) (table 4). Similar 
associations were seen for prescription of alendronic acid in the 60 days prior to the index 
date (data not shown). 
 
DISCUSSION 
This is the first empirical epidemiological study to determine an association between 
bisphosphonates and incident acute pseudogout. We found that people who developed 
incident acute pseudogout were more likely to have received a prescription for an oral 
bisphosphonate in the preceding 60 days than control subjects without pseudogout, matched 
for age, gender and general practice. This association persisted after adjustment for 
confounding comorbid conditions and medications.  Similar associations were seen between 
incident pseudogout and prior prescription of alendronic acid, disodium etidronate, 
risedronate sodium and sodium clodronate, although the numbers receiving prescriptions for 
non-alendronate bisphosphonates were small and only the association with alendronic acid 
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reached statistical significance. The association between prior bisphosphonate use and 
incident acute pseudogout was seen in females but not males. 
 Previous evidence of acute pseudogout occurring as a complication of bisphosphonate 
treatment is limited to anecdotal case reports.
9-14
 Although our study design cannot establish 
causation, it confirms a clear temporal relationship between bisphosphonate prescription and 
subsequent incident acute pseudogout suggested by these earlier reports. Furthermore, 
plausible biological mechanisms exist by which bisphosphonates could predispose to 
CPPD.
21-23
 There were no exposed pseudogout cases who had initiated a bisphosphonate 
greater than 60 days prior to the index date. This suggests that the acute effects of 
bisphosphonates on crystal shedding secondary to hypocalcaemia
21
 might be more important 
than effects on pyrophosphate metabolism.
22,23 
 A recent cross-sectional study reported an 
association between radiographic chondrocalcinosis and low cortical bone mineral density.
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This observation might suggest that the association between bisphosphonates and incident 
acute pseudogout could be explained by channelling bias and reflect a role for osteoporosis, 
the most common indication for bisphosphonate therapy, in the aetiology of CPPD rather a 
specific drug-related effect. However, the authors suggested hyperparathyroidism as the most 
likely underlying mechanism, but in contrast to our study, were unable to adjust for this 
possible confounding relationship. Another possible approach to this conundrum would be to 
compare the risk associated with bisphosphonate use to other drugs used to treat osteoporosis 
(e.g. strontium ranelate). This was not feasible in our study since non-bisphosphonate 
osteoporosis treatments tend to be reserved for highly selected cases who have more severe 
disease or who fail to tolerate or have contra-indications to bisphosphonates, and are rarely 
prescribed in UK primary care.  
We found a statistically significant association between incident acute pseudogout and 
prior alendronic acid prescription and also positive but non-significant associations for 
disodium etidronate, risedronate sodium and sodium clodronate suggesting a possible class 
effect. Interestingly, pseudogout cases were less likely than controls to have been prescribed 
ibandronic acid, although the numbers receiving prescriptions were small and this association 
was not statistically significant. Published case reports describe acute pseudogout occurring 
following administration of oral alendronic acid and disodium etidronate, and intravenous 
pamidronate and neridronate.
9-14
 but there are no published reports of acute pseudogout 
following administration of ibandronic acid. We are unable to definitively explain this 
observation although adherence may be lower with monthly bisphosphonate preparations 
such as ibandronic acid.
34
 It is also possible that prescriptions for monthly drugs such as 
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ibandronic acid could be issued for longer periods, for example three or six months, and 
hence prescriptions issued before the 60-day exposure window would not have been 
captured. Patients receiving ibandronic acid were likely to have been previously prescribed  
alendronic acid (16 out of 24 patients prescribed ibandronic acid) raising the additional 
possibility that individual cases predisposed to CPPD had already experienced incident acute 
pseudogout following previous treatment with alendronic acid.  
Whilst our findings raise the possibility of bisphosphonates as a cause of pseudogout, 
this should not deter clinicians from prescribing them where the risk of fracture warrants their 
use. Indeed, a Cochrane review estimated that the number needed to treat with alendronic 
acid for the secondary prevention of vertebral fracture in post-menopausal women is 16,
35
 
whilst using an estimated prevalence of pseudogout 1.6% in the unexposed, as in our sample 
size calculation, and our unadjusted incidence rate ratio of 1.69, we estimate the number 
needed to harm to be 91.
36
  
By nesting our study within the UK-CPRD and selecting all cases of incident 
pseudogout within the database during the study period, our findings should be generalizable 
to the wider UK primary care population. Matching cases and controls by age, sex and GP 
practice reduces the likelihood of confounding by sociodemographic characteristics. A 
number of limitations of our study are worthy of acknowledgement. First, cases were 
identified by a pseudogout Read code rather than the gold standard of microscopic 
identification of CPP crystals in aspirated synovial fluid risking misclassification bias.
1
 
However, our experience is that pseudogout is rarely diagnosed by general practitioners in the 
UK and it is likely that a pseudogout Read code would be most commonly entered following 
assessment in secondary care where synovial fluid aspiration and crystal identification is 
more commonly performed. It is possible that other conditions, particularly gout, could have 
been misdiagnosed as pseudogout. For this reason, we undertook a sensitivity analysis 
excluding participants with a previous diagnosis of gout, as previously performed in another 
UK primary care database study of risk factors for pseudogout,
8
 without changing our 
findings. Given that pseudogout is rarely diagnosed in primary care, it is perhaps more likely 
that pseudogout is misclassified as another diagnosis, such as gout, which would bias our 
findings towards the null hypothesis. Second, our exposure definition did not include 
intravenous bisphosphonates. We chose to limit our exposure to oral bisphosphonates 
because intravenous bisphosphonates are not prescribed in primary care in the UK and the 
majority of bisphosphonates are orally administered.
18 
Third, we were unable to assess 
bisphosphonate adherence which is often poor. One third to one half of patients are reported 
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to not take bisphosphonates as directed.
37
 However, failure to identify cases of pseudogout 
misclassified as having gout, non-ascertainment of prescription of intravenous 
bisphosphonates, and poor adherence would bias our findings towards the null hypothesis. 
Fourth, there remains a possibility of residual confounding. We adjusted for known risk 
factors for pseudogout but were unable to adjust for hypomagnesaemia.
3,4
 However, we did 
adjust for use of diuretics which are thought to predispose to CPPD via enhanced renal 
magnesium loss.
2,8
 A fifth caveat is the possibility that delay in recording the clinical onset of 
acute pseudogout in the primary care medical record could mean that bisphosphonate 
initiation actually occurred after the onset of acute pseudogout. However, an additional 
sensitivity analysis restricting the definition of bisphosphonate exposure to those who had 
newly initiated a bisphosphonate in a stricter time-period of four weeks prior to the index 
date did not significantly alter our findings (data not shown). Furthermore, such delay in 
recording the pseudogout diagnosis should not differ between those exposed and not exposed 
to a bisphosphonate. Finally, the absolute numbers of cases and controls in younger age-
groups were small raising the possibility that the lack of significant interaction for age is a 
type II error, reflecting insufficient statistical power. 
 Further research is needed to confirm our findings using a robust case definition 
requiring identification of CPP crystals. The risks of CPPD associated with osteoporosis and 
use of intravenous bisphosphonates are worthy of exploration. The relative risks conferred by 
different individual bisphosphonates and the possible protective effect of ibandronic acid also 
warrant investigation in a large adequately-powered study. Finally, the mechanisms by which 
bisphosphonates predispose to CPPD require further elucidation.  The main clinical 
implication of our findings is that prescribers should be aware of acute pseudogout as a 
possible side-effect of bisphosphonate treatment. People presenting with acute pseudogout 
should undergo medication review to look for bisphosphonates as a possible cause. Similarly, 
use of bisphosphonates should be considered carefully in people with known CPPD. 
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